Several MS therapeutics limit MS disease activity and concomitantly expand NK CD56bright cells, including daclizumab (30), alemtuzumab (31), dimethylfumarate (32), and IFN-β (33). The gene discussed is IFNB1; the disease is myeloid sarcoma.